Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 14/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427288 | 1.00 | CA1 (0.44) | CA1CA2CA7CTSKTDP1 | |
| SCHEMBL31059691 | 0.90 | TDP1 (0.46) | CA1CA2CA7CTSKTDP1 | |
| SCHEMBL14533725 | 0.86 | CTSK (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL26035614 | 0.86 | CA1 (0.50) | CA1CA2CA7CTSKTDP1 | |
| SCHEMBL1692753 | 0.86 | CA1 (0.46) | CA1CA2CA7CTSKTDP1 | |
| SCHEMBL30365028 | 0.86 | CA1 (0.46) | CA1CA2CA7CTSKTDP1 | |
| SCHEMBL31255051 | 0.86 | CA1 (0.46) | CA1CA2CA7CTSKTDP1 | |
| SCHEMBL27853976 | 0.85 | CA1 (0.42) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL12133571 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKTDP1 | |
| SCHEMBL31059680 | 0.83 | CTSK (0.44) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4565228-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| CN-114716478-A | 6-substituted phosphoryl quinazoline derivative and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CA1 4537/4885CA2 1774/4885CA7 3241/4885 |
| US-20160347738-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CA1 4537/4885CA2 1774/4885CA7 3241/4885 |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | CA1 1087/4885CA2 3745/4885CA7 4197/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | CA1 359/4885CA2 199/4885CA7 1739/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CA1 4537/4885CA2 1774/4885CA7 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.